Efficacy and Safety of Prophylactic-Dose Anticoagulation Therapy with Intermediate-Therapeutic Doses in Covid-19 Patients

Abstract

Introduction: Coronavirus Disease-19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) was declared a worldwide pandemic on March 11, 2020 and globally, on April 29, 2022, there were 510,270,667 confirmed COVID-19 cases, including 6,233,526 deaths, reported to WHO. As of April 2022, the Government of the Republic of Indonesia has reported 4,249,323 confirmed cases of COVID-19. There have been 143,592 COVID-19-related deaths reported and 4,096,194 patients have recovered from the disease. COVID-19 is associated with a high risk of venous thromboembolism (VTE), however, to date, optimal prophylactic anticoagulant therapy remains uncertain and may depend on the severity of COVID-19. Objective(s): The aim of this study was to determine the difference in efficacy and safety in administering prophylactic doses with intermediate/therapeutic doses in confirmed COVID-19 patients. Result(s): This study used 6 studies that met the inclusion of differences in efficacy and safety in administering prophylactic doses with intermediate/therapeutic doses in confirmed COVID-19 patients. Conclusion(s): From 6 studies, there were 2 studies comparing anticoagulant prophylactic doses with intermediate doses and 4 studies comparing anticoagualnt prophylactic doses with therapeutic doses. In all studies, there were no significant differences in thromboembolic events or all-cause mortality in COVID-19 patients. The incidence of bleeding at the intermediate and therapeutic doses increased compared to the prophylactic dose, but the difference was not significant. Copyright © 2023, Institute of Medico-legal Publication. All rights reserved.